Safety Evaluation of LSCD101 Transplantation for Limbal Stem Cell Deficiency
Status:
Completed
Trial end date:
2021-01-14
Target enrollment:
Participant gender:
Summary
Clinical Study Objective:
To evaluate the tolerability and safety after transplantation of LSCD101 in patients with
intractable limbal stem cell deficiency
Study Method:
Subjects who finally meet the inclusion/exclusion criteria results of the subject eligibility
evaluation will receive transplantation of the investigational product. Adverse drug reaction
will be confirmed during 24 weeks after transplantation.